Crown Bioscience, a global contract research organization, agreed to acquire IndivuServ business unit of Indivumed, a firm engaged in the provision and analysis of clinical biospecimens. Financial terms were not disclosed. “The acquisition of ‘Indivumed Services’ reflects Crown Bioscience’s commitment to expanding our translational research platforms to provide our customers with superior options for bridging the gap between preclinical and clinical research. Everyone at Crown Bioscience is delighted to be welcoming the talented staff of ‘Indivumed Services’ to the company, and excited about the long-term potential of our new relationship," Armin Spura, Crown Bioscience CEO.